First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized ImmunotherapyFirst Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy